Biotech marketing for investor relations, scientific communications, and commercial readiness

A biotech marketing agency builds investor relations programs, scientific communications, KOL (Key Opinion Leader) engagement, and commercial-readiness marketing for biotech, pharma, and life sciences companies. Empire325 biotech engagements span pre-clinical positioning, clinical milestone communications, IPO/SPAC roadshow support, partnership marketing, and (post-approval) commercial launch programs.

Three differences: (1) Audiences are highly technical (PIs, KOLs, regulators, institutional investors) requiring scientific accuracy, not consumer-style positioning. (2) Communications must respect SEC fair disclosure rules, FDA promotional restrictions, and clinical trial blackout periods. (3) Long timelines — pre-clinical to commercial can take 7-15 years, requiring sustained narrative investment without short-term traffic metrics as proof.

Every campaign and content piece enters a documented review pipeline aligned with the company's regulatory and legal counsel. We work alongside MLR (Medical/Legal/Regulatory) review teams, not around them. For investor-facing communications, we respect Reg FD, IPO quiet periods, and SEC Marketing Rule applicable provisions.

Pre-clinical and clinical-stage biotech, biopharmaceutical companies, medical device firms, diagnostics companies, contract research organizations (CROs), AI-drug-discovery platforms, gene therapy and cell therapy companies, and biotech-focused investors (VC funds, biotech hedge funds).

Empire325 biotech engagements typically range $20K-$100K monthly retainers depending on scope, regulatory complexity, and IR/commercial mix. Implementation projects (IR site rebuilds, KOL programs, IPO marketing infrastructure) range $40K-$250K project-based. Discovery scoping is provided after a 30-minute call.